JP2009537598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537598A5 JP2009537598A5 JP2009511492A JP2009511492A JP2009537598A5 JP 2009537598 A5 JP2009537598 A5 JP 2009537598A5 JP 2009511492 A JP2009511492 A JP 2009511492A JP 2009511492 A JP2009511492 A JP 2009511492A JP 2009537598 A5 JP2009537598 A5 JP 2009537598A5
- Authority
- JP
- Japan
- Prior art keywords
- diaza
- bicyclo
- pain
- alkyl
- nonane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- XJKNACDCUAFDHD-UHFFFAOYSA-N 1,4-diazabicyclo[3.2.2]nonane Chemical class C1CC2CCN1CCN2 XJKNACDCUAFDHD-UHFFFAOYSA-N 0.000 claims 8
- 208000002193 Pain Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- -1 cyano, nitro, amino Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000013403 hyperactivity Diseases 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- YJKZDNLYNPDKNW-UHFFFAOYSA-N (9-hydroxy-9h-fluoren-2-yl) 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate Chemical compound C1=C2C(O)C3=CC=CC=C3C2=CC=C1OC(=O)N1CCN2CCC1CC2 YJKZDNLYNPDKNW-UHFFFAOYSA-N 0.000 claims 1
- ZAEMKVYOAFXYGE-UHFFFAOYSA-N (9-oxofluoren-2-yl) 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate Chemical compound C=1C=C2C3=CC=CC=C3C(=O)C2=CC=1OC(=O)N1CCN2CCC1CC2 ZAEMKVYOAFXYGE-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000026097 Factitious disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010052276 Pseudodementia Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- XWXKCKBGBWKVJU-UHFFFAOYSA-N dibenzofuran-3-yl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate Chemical compound C=1C=C(C2=CC=CC=C2O2)C2=CC=1OC(=O)N1CCN2CCC1CC2 XWXKCKBGBWKVJU-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 201000009863 inflammatory diarrhea Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- MHIBXAXPJSPKLN-UHFFFAOYSA-N n-(9h-fluoren-2-yl)-1,4-diazabicyclo[3.2.2]nonane-4-carboxamide Chemical compound C=1C=C(C2=CC=CC=C2C2)C2=CC=1NC(=O)N1CCN2CCC1CC2 MHIBXAXPJSPKLN-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000016160 smooth muscle contraction Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
Claims (9)
- 式Iによって表される1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体又は医薬として許容可能なその塩
[式中、
Xは、O又はNHを表し、
Yは、O、S、CO、SO、SO2、CH2、CHOH、又はC=N−OZを表し、Zは、水素又はアルキルを表し、並びに
R’、R’’、R’’’、及びR’’’’は、互いに独立に、水素、アルキル、シクロアルキル、シクロアルキル−アルキル、ヒドロキシ、アルコキシ、ハロ、ハロアルキル、ハロアルコキシ、シアノ、ニトロ、アミノ、オキソ、カルボキシ、アルキル−カルボニル、アルコキシ−カルボニル、アルキル−カルボニル−オキシ、カルバモイル、アミド、スルファモイル、フェニル、又はベンジルを表す]。 - XがO又はNHを表す、請求項1に記載の1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体又は医薬として許容可能なその塩。
- Yが、O、S、CO、SO、SO2、CH2、CHOH、又はC=N−OZを表し、Zが水素又はアルキルを表す、請求項1又は2に記載の1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体又は医薬として許容可能なその塩。
- R’、R’’、R’’’、及びR’’’’が、互いに独立に、水素、アルキル、シクロアルキル、シクロアルキル−アルキル、ヒドロキシ、アルコキシ、ハロ、ハロアルキル、ハロアルコキシ、シアノ、ニトロ、アミノ、オキソ、カルボキシ、アルキル−カルボニル、アルコキシ−カルボニル、アルキル−カルボニル−オキシ、カルバモイル、アミド、スルファモイル、フェニル、又はベンジルを表す、請求項1から3までのいずれか一項に記載の1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体又は医薬として許容可能なその塩。
- R’、R’’、R’’’、及びR’’’’が全て水素を表す、請求項4に記載の1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体又は医薬として許容可能なその塩。
- 1,4−ジアザ−ビシクロ[3.2.2]ノナン−4−カルボン酸9−オキソ−9H−フルオレン−2−イルエステル、
1,4−ジアザ−ビシクロ[3.2.2]ノナン−4−カルボン酸9H−フルオレン−2−イルエステル、
1,4−ジアザ−ビシクロ[3.2.2]ノナン−4−カルボン酸ジベンゾフラン−3−イルエステル、
1,4−ジアザ−ビシクロ[3.2.2]ノナン−4−カルボン酸(9H−フルオレン−2−イル)−アミド、
1,4−ジアザ−ビシクロ[3.2.2]ノナン−4−カルボン酸9−ヒドロキシ−9H−フルオレン−2−イルエステルである、
請求項1に記載の1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体又は医薬として許容可能なその塩。 - 請求項1から6までのいずれか一項に記載の治療有効量の1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体、又は医薬として許容可能なその付加塩、又はそのプロドラッグを、少なくとも1つの医薬として許容可能な担体又は希釈剤と一緒に含む医薬組成物。
- 請求項1から6までのいずれか一項に記載の治療有効量の1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体又は医薬として許容可能なその付加塩を含む、コリン作動性受容体及び/又はモノアミン受容体の調節に対して応答性である、ヒトを含む哺乳動物の疾患又は障害又は状態を治療、予防、又は緩和するための医薬組成物/医薬品。
- 前記疾患、障害、又は状態が、認知障害、学習障害、記憶欠損及び記憶障害、ダウン症候群、アルツハイマー病、注意欠陥、注意欠陥多動性障害(ADHD)、トゥーレット症候群、精神病、うつ病、双極性障害、躁病、躁うつ病、統合失調症、統合失調症に関係する認知障害又は注意欠陥、強迫性障害(OCD)、パニック障害、神経性食欲不振、過食症、及び肥満などの摂食障害、ナルコレプシー、侵害受容、AIDS−認知症、老年性認知症、自閉症、パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、不安症、非OCD不安障害、痙攣性疾患、てんかん、神経変性障害、一過性無酸素症、誘発性神経変性、神経障害、糖尿病性神経障害、末梢性失読症、遅発性ジスキネジー、運動過剰症、軽度疼痛、中程度又は重度疼痛、急性、慢性若しくは再発性の疼痛、片頭痛によって生じる疼痛、術後疼痛、幻肢痛、炎症性疼痛、神経障害性疼痛、慢性頭痛、中心性疼痛、糖尿病性神経障害に関係する疼痛、治療後神経痛に関係する疼痛、若しくは末梢神経損傷に関係する疼痛、過食症、外傷後症候群、社会恐怖症、睡眠障害、偽認知症、ガンザー症候群、月経前症候群、後期黄体期症候群、線維筋痛、慢性疲労症候群、無言症、抜毛癖、時差ぼけ、不整脈、平滑筋収縮、狭心症、早産、下痢、喘息、遅発性ジスキネジー、運動過剰症、早漏、勃起困難、高血圧、炎症性疾患、炎症性皮膚疾患、座瘡、酒さ、クローン病、炎症性腸疾患、潰瘍性大腸炎、下痢、又は煙草などのニコチン含有製品、ヘロイン、コカイン、及びモルヒネなどのオピオイド、ベンゾジアゼピン及びベンゾジアゼピン様薬物、並びにアルコールを含む中毒性物質の使用の中止によって生じる禁断症状である、請求項8に記載の医薬組成物/医薬品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80252806P | 2006-05-23 | 2006-05-23 | |
DKPA200600704 | 2006-05-23 | ||
PCT/EP2007/054869 WO2007135120A1 (en) | 2006-05-23 | 2007-05-21 | Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009537598A JP2009537598A (ja) | 2009-10-29 |
JP2009537598A5 true JP2009537598A5 (ja) | 2010-06-24 |
Family
ID=38458224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009511492A Abandoned JP2009537598A (ja) | 2006-05-23 | 2007-05-21 | 新規1,4−ジアザ−ビシクロ[3.2.2]ノナン誘導体及びそれらの医学的使用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090118265A1 (ja) |
EP (1) | EP2029594B1 (ja) |
JP (1) | JP2009537598A (ja) |
WO (1) | WO2007135120A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2692004C (en) * | 2007-06-15 | 2013-04-09 | Board Of Regents, The University Of Texas System | Methods and compositions to inhibit edema factor and adenylyl cyclase |
JP2011504909A (ja) * | 2007-11-30 | 2011-02-17 | ノイロサーチ アクティーゼルスカブ | 新規なカルボン酸4−フェニルアゾ−フェニルエステル誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用 |
US9045098B2 (en) * | 2009-12-01 | 2015-06-02 | Honda Motor Co., Ltd. | Vocabulary dictionary recompile for in-vehicle audio system |
CN107188900B (zh) * | 2017-05-27 | 2019-09-06 | 北京师范大学 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
RU2668982C1 (ru) * | 2017-10-10 | 2018-10-05 | Федеральное государственное бюджетное учреждение науки Институт молекулярной генетики Российской академии наук | Меченный тритием 3,7-бис(2,3-дигидро-1-бензофуран-5-илкарбонил)-1,5-диметил-3,7-диазабицикло[3.3.1]нонан-9-он |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2791678B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
ES2275808T3 (es) | 2001-02-06 | 2007-06-16 | Pfizer Products Inc. | Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos. |
US7067507B2 (en) * | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
US7365193B2 (en) * | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
-
2007
- 2007-05-21 US US12/300,010 patent/US20090118265A1/en not_active Abandoned
- 2007-05-21 JP JP2009511492A patent/JP2009537598A/ja not_active Abandoned
- 2007-05-21 WO PCT/EP2007/054869 patent/WO2007135120A1/en active Application Filing
- 2007-05-21 EP EP07729313A patent/EP2029594B1/en not_active Not-in-force
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009538867A5 (ja) | ||
JP2009538870A5 (ja) | ||
JP2009538869A5 (ja) | ||
RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
US7420056B2 (en) | Substituted bicyclic imidazo-3-ylamine compounds | |
JP2008530171A5 (ja) | ||
JP2009538866A5 (ja) | ||
JP2009537599A5 (ja) | ||
JP2008530172A5 (ja) | ||
RU2006131454A (ru) | Новые производные мочевины и их медицинское применение | |
JP2007530635A5 (ja) | ||
JP2009537598A5 (ja) | ||
JP2006508109A5 (ja) | ||
JP2007520525A5 (ja) | ||
JP2009526814A5 (ja) | ||
JP2010535738A5 (ja) | ||
JP2009526776A5 (ja) | ||
NZ601088A (en) | Alpha 4 beta 2 neuronal nicotinic acetylcholine receptor ligands | |
WO2009127944A8 (en) | Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors | |
JP2008526706A5 (ja) | ||
RU2010114662A (ru) | Новые производные 1,4-диазабицикло(3.2.2)нонилпиримидина и их медицинское применение | |
JP2005530814A5 (ja) | ||
RU2010135035A (ru) | Новые триарильные производные, полезные в качестве модуляторов никотиновых ацетилхолиновых рецепторов | |
JP2009537600A5 (ja) | ||
JP2009526024A5 (ja) |